News Overview
November 2, 2009
Successful purchase of trait platform with extensive product pipeline:
Bayer CropScience completes acquisition of biotech company Athenix Corp.
» more
Bayer CropScience completes acquisition of biotech company Athenix Corp.
» more
October 27, 2009
Renewed year-on-year growth in underlying EBITDA in the third quarter of 2009:
Bayer back on the uptrend
» more
1:15 min.
Bayer back on the uptrend
» more
1:15 min.October 23, 2009
New prizes from the Bayer Science & Education Foundation:
Bayer Early Excellence in Science Award 2009: EUR 30,000 for young research scientists
» more
Bayer Early Excellence in Science Award 2009: EUR 30,000 for young research scientists
» more
October 22, 2009
Swiss regulatory authority Swissmedic announces results of its analysis of current studies on the risks of hormonal contraceptives:
The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market
» more
The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market
» more
October 9, 2009
Improvement in orders
Bayer MaterialScience AG ends reduced working hours at German sites
» more
Bayer MaterialScience AG ends reduced working hours at German sites
» more
October 9, 2009
September 23, 2009
Phase II Study in Advanced Breast Cancer:
Nexavar® in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
» more
Nexavar® in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
» more
September 22, 2009
Leading-edge medical research and development:
Bayer researchers nominated for the “Deutscher Zukunftspreis” awarded by the German Federal President
» more
Bayer researchers nominated for the “Deutscher Zukunftspreis” awarded by the German Federal President
» more
September 22, 2009
Once again included in the Carbon Disclosure Leadership Index
Bayer honored as world’s best company in climate protection
» more
1:19 min.
Bayer honored as world’s best company in climate protection
» more
1:19 min.September 22, 2009
Results of a Phase II study in Renal Cell Carcinoma (RCC):
Bayer’s Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
» more
1:28 min.
Bayer’s Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
» more
1:28 min.September 17, 2009
Greater focus on future technologies:
Bayer CropScience accelerates expansion of biotech and seed business with investments of around EUR 3.5 billion through 2018
» more
1:49 min.
Bayer CropScience accelerates expansion of biotech and seed business with investments of around EUR 3.5 billion through 2018
» more
1:49 min.September 15, 2009
Bayer Supervisory Board decides company’s future management line-up:
Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010
» more
Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010
» more
September 4, 2009
Bayer again included in the Dow Jones Sustainability World Index:
Bayer remains “best in class” in sustainability
» more
Bayer remains “best in class” in sustainability
» more
September 3, 2009
September 2, 2009
August 30, 2009
Bayer Committed to Prevention of Arterial Thrombosis:
Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban (ROCKET AF)
» more
Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban (ROCKET AF)
» more
August 20, 2009
Nine-year-old Russian girl wins international children’s painting competition:
Children’s pictures challenge climate change
» more
Children’s pictures challenge climate change
» more
August 19, 2009
Trait platform with extensive product pipeline to deliver innovative solutions for farmers:
Bayer CropScience acquires US biotech company Athenix Corp.
» more
1:17 min.
Bayer CropScience acquires US biotech company Athenix Corp.
» more
1:17 min.July 29, 2009
Interim report for the second quarter of 2009:
Bayer robust in a difficult environment
» more
Bayer robust in a difficult environment
» more
more News
Press Newsletter
